PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 5.15

Change

+0.30 (+6.19)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

+1.71 (+16.62%)

USD 8.14B
QLD ProShares Ultra QQQ

+4.61 (+5.69%)

USD 5.50B
SSO ProShares Ultra S&P500

+3.08 (+4.15%)

USD 4.33B
FNGU MicroSectors FANG+ Index 3X Le..

N/A

USD 4.29B
UPRO ProShares UltraPro S&P500

+3.78 (+6.20%)

USD 2.91B
TECL Direxion Daily Technology Bull..

+5.25 (+11.29%)

USD 1.95B
YINN Direxion Daily FTSE China Bull..

+0.65 (+2.01%)

USD 1.19B
USD ProShares Ultra Semiconductors

+3.33 (+9.74%)

USD 0.61B
UDOW ProShares UltraPro Dow30

+2.61 (+3.72%)

USD 0.56B
LABU Direxion Daily S&P Biotech Bul..

+3.47 (+6.57%)

USD 0.53B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.46% 25% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.46% 25% F 8% B-
Trailing 12 Months  
Capital Gain -14.45% 36% F 20% F
Dividend Return 0.85% 61% D- 16% F
Total Return -13.60% 36% F 18% F
Trailing 5 Years  
Capital Gain -61.60% 6% D- 6% D-
Dividend Return 2.09% 15% F 4% F
Total Return -59.51% 6% D- 5% F
Average Annual (5 Year Horizon)  
Capital Gain 52.17% 88% B+ 95% A
Dividend Return 52.79% 88% B+ 95% A
Total Return 0.62% 42% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 392.87% 7% C- 3% F
Risk Adjusted Return 13.44% 25% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.